Rhythm hits record high as drug reduces weight in rare type of obesity

Rhythm Pharmaceuticals

09/07/2025 14:55

Updates

   ** Shares of Rhythm Pharmaceuticals RYTM.O jump 23.7% to record high of $80.7

** Experimental drug bivamelagon showed reductions in body mass index at 14 weeks of treatment in patients with acquired hypothalamic obesity

** Tested the drug in a mid-stage trial of 28 patients aged 12 years or older

** Plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design

** Acquired hypothalamic obesity is a rare form of obesity that occurs following damage to the hypothalamic region of the brain

** Including session's move, stock up ~44% YTD

 (Reporting by Sriparna Roy and Christy Santhosh in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))